Avalo Therapeutics (AVTX) Depreciation and Depletion (2014 - 2017)
Avalo Therapeutics (AVTX) reported Depreciation and Depletion of $4906.0 for Q4 2017, down 23.2% on a YoY basis from $6388.0 in Q4 2016, and down 8.49% quarter-over-quarter from $5361.0 in Q3 2017.
Avalo Therapeutics (AVTX) Depreciation and Depletion (2014 - 2017) Analysis & Trends
Avalo Therapeutics has reported Depreciation and Depletion for 4 years, with the latest figure at $4906.0 in Q4 2017.
- For the quarter ending Q4 2017, Depreciation and Depletion fell 23.2% year-over-year to $4906.0; the trailing twelve-month figure through Dec 2017 stood at $21956.0 (down 18.25% YoY), and the FY2025 full-year result was $300000.0, up 50.0% from the prior year.
- Depreciation and Depletion for Q4 2017 stood at $4906.0, down from $5361.0 in the prior quarter.
- The five-year high for Depreciation and Depletion was $7881.0 in Q4 2014, with the low at $4906.0 in Q4 2017.
- Historically, Depreciation and Depletion has averaged $6169.3 across 4 years, with a median of $6148.0 in 2015.
- Annual changes were most pronounced in 2016 — Depreciation and Depletion advanced 22.99% — and 2017, when it declined 23.98%.
- Avalo Therapeutics' Depreciation and Depletion stood at $7881.0 in 2014, then retreated by 21.99% to $6148.0 in 2015, then gained by 3.9% to $6388.0 in 2016, then decreased by 23.2% to $4906.0 in 2017.
- The last three Depreciation and Depletion figures came in at $4906.0 (Q4 2017), $5361.0 (Q3 2017), and $5859.0 (Q2 2017), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 4,906.00 |
| Dec 31, 2017 | 4,906.00 |
| Sep 30, 2017 | 5,361.00 |
| Sep 30, 2017 | 5,361.00 |
| Jun 30, 2017 | 5,859.00 |
| Jun 30, 2017 | 5,859.00 |
| Mar 31, 2017 | 5,830.00 |
| Mar 31, 2017 | 5,830.00 |
| Dec 31, 2016 | 6,388.00 |
| Dec 31, 2016 | 6,388.00 |
| Sep 30, 2016 | 7,052.00 |
| Sep 30, 2016 | 7,052.00 |
| Jun 30, 2016 | 6,628.00 |
| Jun 30, 2016 | 6,628.00 |
| Mar 31, 2016 | 6,788.00 |
| Mar 31, 2016 | 6,788.00 |
| Dec 31, 2015 | 6,148.00 |
| Dec 31, 2015 | 6,148.00 |
| Sep 30, 2015 | 6,322.00 |
| Sep 30, 2015 | 6,322.00 |